Abstract

BackgroundThe cannabinoid CB2 receptor (CB2R), which is a target to afford neuroprotection, and N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors, which are key in mediating excitatory neurotransmission, are expressed in both neurons and glia. As NMDA receptors are the target of current medication in Alzheimer’s disease patients and with the aim of finding neuromodulators of their actions that could provide benefits in dementia, we hypothesized that cannabinoids could modulate NMDA function.MethodsImmunocytochemistry was used to analyze the colocalization between CB2 and NMDA receptors; bioluminescence resonance energy transfer was used to detect CB2-NMDA receptor complexes. Calcium and cAMP determination, mitogen-activated protein kinase (MAPK) pathway activation, and label-free assays were performed to characterize signaling in homologous and heterologous systems. Proximity ligation assays were used to quantify CB2-NMDA heteromer expression in mouse primary cultures and in the brain of APPSw/Ind transgenic mice, an Alzheimer’s disease model expressing the Indiana and Swedish mutated version of the human amyloid precursor protein (APP).ResultsIn a heterologous system, we identified CB2-NMDA complexes with a particular heteromer print consisting of impairment by cannabinoids of NMDA receptor function. The print was detected in activated primary microglia treated with lipopolysaccharide and interferon-γ. CB2R activation blunted NMDA receptor-mediated signaling in primary hippocampal neurons from APPSw/Ind mice. Furthermore, imaging studies showed that in brain slices and in primary cells (microglia or neurons) from APPSw/Ind mice, there was a marked overexpression of macromolecular CB2-NMDA receptor complexes thus becoming a tool to modulate excessive glutamate input by cannabinoids.ConclusionsThe results indicate a negative cross-talk in CB2-NMDA complexes signaling. The expression of the CB2-NMDA receptor heteromers increases in both microglia and neurons from the APPSw/Ind transgenic mice, compared with levels in samples from age-matched control mice.

Highlights

  • Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting more than 46 million people worldwide

  • The NMDAR interacts with the ­CB2R in a heterologous expression system The NMDA receptor plays a central role in excitatory neurotransmission, being a therapeutic target to combat AD

  • The human embryonic kidney HEK-293T cell model was transfected with the cDNAs for C­ B2R fused to YFP, for the GluN1 NMDAR subunit fused to Renilla luciferase

Read more

Summary

Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting more than 46 million people worldwide. Excitatory glutamatergic neurotransmission is required for neuronal survival and synaptic plasticity; aberrant activity promotes excitotoxicity and cell death [4, 5]. The NMDA receptor (NMDAR) plays an important role in neuronal plasticity and learning mechanisms. Activation of synaptic NMDARs has been reported to control synaptic plasticity and stimulate cell survival, while activation of extrasynaptic NMDARs promotes cell death and contributes to the etiology of AD. The cannabinoid C­ B2 receptor ­(CB2R), which is a target to afford neuroprotection, and N-methyl-Daspartate (NMDA) ionotropic glutamate receptors, which are key in mediating excitatory neurotransmission, are expressed in both neurons and glia. As NMDA receptors are the target of current medication in Alzheimer’s disease patients and with the aim of finding neuromodulators of their actions that could provide benefits in dementia, we hypothesized that cannabinoids could modulate NMDA function

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.